This content is from: Features

Learning from Novartis: India in the quid pro quo world

The Novartis case shone a spotlight on India’s unique patent system. Deepa Kachroo Tiku and Taapsi Johri Singh explore the questions and uncertainties raised by the controversial decision

To access our in-house intelligence please request a trial here.

Read this article – and more – for a 30 day period.


Are you already an Managing IP subscriber? Login here

Instant access to all of our content. Membership Options | 30 Day Trial